Compare DexCom, Inc. (DXCM) vs Nerdwallet Inc (NRDS) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

NRDS trades at $9.55, up 1.81% today, with strong technical momentum showing bullish moving average signals. The company demonstrates impressive financial improvement with revenue growing from $539M in 2022 to $837M in 2025, achieving profitability with net income of $49M. Recent earnings beats and a 66.7% analyst buy rating support positive sentiment, though RSI levels suggest some near-term caution.

The stock offers attractive valuation with P/E of 10.25 and P/S of 0.83, trading below the $12.75 consensus target. Key risks include execution of the business pivot and market volatility, but strong cash flow generation and improving margins provide fundamental support for potential upside.